Skip to main content
RB logo RB logo
5.000.00 GBX +3.00 (0.2%)
  • About us
    About us

    We create simple, innovative products that make it easy for individuals, families and communities to live healthier and happier.

    About us
    • Who we are
    • Our purpose and compass
    • Our Leadership
    • Contact us
    • Coronavirus information
  • Brands
    Brands

    Available in nearly 200 countries, our brands are loved and trusted by people all over the world.

    Brands
    • Clearasil
    • Enfa
    • Finish
    • Lysol
    • Veet
    • Dettol
    • Air Wick
    • Durex
    • Calgon
    • Mortein
    • Cillit Bang
    • Nurofen
    • Nutramigen
    • Scholl
    • Strepsils
    • Woolite
    • Vanish
    • Harpic
  • Careers
    Careers

    We are the community behind some of the world’s most beloved brands. Together we shape healthier lives and happier homes for people across the globe.

    Careers
    • Our people
      • Clare
      • Rakshet
      • Sunny
      • Yawer
      • Caroline
  • Investors
    Investors

    RB is a global consumer goods company listed within the top 25 of the London Stock Exchange.

    Investors
    • Investor information
    • The Board
    • Investor tools
      • Regulatory news
      • Share price calculator
      • Historical share price
      • Detailed share price
    • Corporate Governance
      • RB Subsidiaries
    • Your shareholding
      • AGM
      • ADR Information
      • Dividend information
      • Debt investors
      • Dividend payments
    • Annual report 2019
  • Sustainability
    Sustainability

    We exist to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. This means operating in a responsible and sustainable way while innovating products that improve lives while reducing environmental impacts.

    Sustainability
    • The RB Fight for Access Fund
    • Our approach
    • Key issues and stakeholders
    • Sustainable business
      • Sustainable innovation
      • Product safety and stewardship
      • Plastics and packaging
      • Infant and child nutrition
      • Business ethics
      • Humidifier sanitizer
      • The Economic Impact of RB in the US
    • Environment
      • Climate change and energy
      • Water
      • Responsible supply chain and sourcing
      • Waste from operations
    • People and communities
      • People and culture
      • Gender pay
      • Health and safety
      • Social impact investment
      • Human rights
    • Recognition and partnerships
    • Performance data
    • Policies and reports
  • Newsroom
    Newsroom

    See the latest news and investor news from RB. Find investor information and see what the media are saying about RB.

    Newsroom
    • Latest News
  • Innovation
    Innovation
    Innovation
    • Hygiene Innovation
      • Our key verticals
    • Health Innovation
      • Our innovation focus
      • The Future Consumer
    • Scale your business
    • Innovation Labs
    • Partner with us
    • Submit an idea
    • The future of self-care
Our global sites

Explore our global sites with local content specific to each country.

  • Global

  • Japan

  • Brazil

  • Germany

  • Russia

  • USA

  • Korea

rb logo
6,164.00 GBX+76.00 +1.25%
Your search for ' ' returned the following results:
You are viewing of results
Home Media

Proposed demerger

  • Media

Proposed demerger of the RB Pharmaceuticals business

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

THIS ANNOUNCEMENT IS NOT A PROSPECTUS BUT AN ADVERTISEMENT AND INVESTORS SHOULD NOT ACQUIRE ANY ORDINARY SHARES IN EITHER RECKITT BENCKISER GROUP PLC OR INDIVIOR PLC REFERRED TO IN THIS ANNOUNCEMENT EXCEPT ON THE BASIS OF THE INFORMATION CONTAINED IN THE PROSPECTUS TO BE PUBLISHED BY INDIVIOR PLC AND ANY SUPPLEMENT OR AMENDMENT THERETO

Following the announcement made by Reckitt Benckiser Group plc (RB) on 28th July 2014 that it was pursuing a demerger of the RB Pharmaceuticals (RBP) business with a separate UK listing, RB today announces the detailed proposed timetable for the demerger (the Demerger).

  • New demerged RBP company, to be called Indivior PLC (Indivior), will be UK domiciled and admitted to the premium listing segment of the Official List and traded on the London Stock Exchange’s main market for listed securities.
  • RB circular to shareholders and Indivior prospectus will be published later today setting out the background to, and reasons for, the Demerger and detailed information on Indivior.
  • RB General Meeting to approve the Demerger will be held on 11 December 2014.
  • If the Demerger proceeds, RB Shareholders who are registered on the RB share register at the Demerger record date will receive one Indivior ordinary share for each RB ordinary share held.
  • Demerger expected to complete and Indivior shares to commence trading on 23 December 2014.



The Board of RB considers that the Demerger is in the best interests of both RB and Indivior and will result in a stronger future for both RB and Indivior, with the Boards of each company focused on developing their respective businesses into leaders in their specific sectors. In particular, the Board of RB considers that the profile and potential risks and rewards of Indivior, as a specialty pharmaceuticals company, will be better understood as a standalone listed business. RB will continue its focus as a consumer health and hygiene company. 

Commenting today, Adrian Bellamy, Chairman of RB said: 

"The Board of RB considers that the Demerger is in the best interests of RB Shareholders. Accordingly the Board of RB unanimously recommends shareholders to vote in favour of the Demerger at the General Meeting to be held on 11 December 2014."

Commenting today, Howard Pien, Chairman of Indivior, said:

"Indivior, under the leadership of Shaun Thaxter, has built a global, industry leading company in addiction treatment. The business has a profitable opioid addiction business and a strong pipeline that has the potential to revolutionise how the chronic disease is treated worldwide. I, and our newly formed Board, are delighted to lead Indivior through its next stage of evolution."

Commenting today, Shaun Thaxter, CEO of Indivior, said:

"I look forward to partnering with the Indivior Executive Committee and Board to further build upon the strong foundation set by Reckitt Benckiser Pharmaceuticals under the guidance of RB as we transition to a sustainable, stand-alone organisation. Our full team – from the Executive Committee to the Board to our employees – is energised by the opportunity to continue leveraging our unique patient-focused leadership model to expand availability of addiction treatment and improve patient lives across the globe."

Download press release as a PDF

Address

Registered office at 103 - 105 Bath Road, Slough, Berkshire, SL1 3UH

Registered in England & Wales, No 6270876

rb.com

  • About us
  • Brands
  • Careers
  • Investors
  • Sustainability
  • Newsroom
  • Innovation

More

  • Terms and Conditions
  • Privacy Policy
  • Cookie Policy
  • Modern Slavery Act Statement

© Copyright Reckitt Benckiser Group plc. All rights reserved